Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs
Advanced Science · 2024-10 · 11 (40)
DOI: 10.1002/advs.202400757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.08.2024. Verfasst von Lidan Zeng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, 30322, USA. Hauptthemen laut MEDLINE: V-Set Domain-Containing T-Cell Activation Inhibitor 1, Ubiquitin Thiolesterase, Immunoconjugates. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Winship Cancer Institute, Emory University.
Abstract (Originalsprache)
Tuning immune‐cold tumor hot has largely attracted attention to improve cancer treatment, including immunotherapy and antibody‐drug conjugates (ADCs). Utilizing multiomic analyses and experimental validation, this work identifies a pivotal role for the USP10/B7‐H4 proteolytic axis in mediating the interplay between tumor immune responses and ADC efficacy, particularly for sacituzumab govitecan (SG) in treating triple negative breast cancers (TNBCs). Mechanistically, the inhibition of autocrine motility factor receptor (AMFR)‐mediated ubiquitylation of B7‐H4 by the deubiquitinase USP10 leads to the stabilization of B7‐H4, which suppresses tumor immune activity and reduces SG treatment effectiveness. Pharmacological inhibition of USP10 promotes the degradation of B7‐H4, enhancing tumor immunogenicity and consequently improving the tumor‐killing efficacy of SG. In preclinical TNBC models, suppression of USP10/B7‐H4 proteolytic axis is effective in increasing SG killing efficacy and reducing tumor growth, especially for the tumors with the USP10 high /B7‐H7 high signature. Collectively, these findings uncover a novel strategy for targeting the immunosuppressive molecule B7‐H4 for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
- Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 30322, USA.
- DGP graduate program, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
- Department of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
- Department of Chemistry, College of Arts and Science, Emory University, Atlanta, GA, 30322, USA.
- Department of Medicine, Weill Cornell Medicine, New York, NY, 10065, USA.
ORCID-Profile: Yong Wan
Förderung
- NCI NIH HHS
- Winship Cancer Institute
- Emory University
- National Cancer Institute
Zitieren
APA
Zeng, L., Zhu, Y., Cui, X., Chi, J., Uddin, A., Zhou, Z., Song, X., Dai, M., Cristofanilli, M., Kalinsky, K., & Wan, Y. (2024). Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs. Advanced Science, 11(40). https://doi.org/10.1002/advs.202400757
Vancouver
Zeng L, Zhu Y, Cui X, Chi J, Uddin A, Zhou Z, et al. Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs. Advanced Science. 2024;11(40). doi:10.1002/advs.202400757
BibTeX
@article{Zeng2024,
author = {Zeng, Lidan and Zhu, Yueming and Cui, Xin and Chi, Junlong and Uddin, Amad and Zhou, Zhuan and Song, Xinxin and Dai, Mingji and Cristofanilli, Massimo and Kalinsky, Kevin and Wan, Yong},
title = {Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {40},
doi = {10.1002/advs.202400757}
}
EUVIMED